155 results about "Glucosidase activity" patented technology

The invention provides a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function and application thereof, and belongs to the technical field of functional microorganisms. The invention relates to a bifidobacterium animalis subsp. Lactis strain B21247 with a hypoglycemic function. The preservation number of the bifidobacterium animalis subsp. Lactis strain B21247 is GDMCC No: 65075. The strain B21247 has a good intestinal colonization function, and has the activity of inhibiting alpha-glucosidase in vitro. Meanwhile, a type 2 diabetes mouse model is used as an experimental model to verify that the strain B21247 achieves the effect of reducing blood sugar by adjusting glycosylated hemoglobin, reducing pancreatic beta cell damage and increasing secretion of intestinal GLP-1, and a new thought is provided for reducing blood sugar or treating diabetes.

The invention belongs to the technical field of biology, and discloses a Tibetan pig source bacillus subtilis, the classification name is bacillus subtilis Yirun2024, the Latin name is bacillus subtilis Yirun2024, the preservation number is CCTCC NO: M 20241752, the preservation date is August 7, 2024, the preservation unit is China Center for Type Culture Collection, and the preservation address is Wuhan University, Wuhan, China. When the bacillus subtilis is fermented for 12 hours in a shake flask, the endo-cellulase activity, the exo-cellulase activity and the beta-glucosidase activity of the bacillus subtilis are respectively up to 2902.72 U / mL, 11026.33 U / mL and 2983.04 U / mL, which are far better than those of similar engineering bacteria. Meanwhile, the invention further provides application of the bacillus subtilis, the bacillus subtilis has important significance in the field of promotion of application of fiber resources, and meanwhile, the bacillus subtilis can keep a high survival rate in a high-temperature environment.

The name of the invention is application of Peniazathilone A as an alpha-glucosidase inhibitor and a preparation method of the Peniazathilone A. The invention belongs to the technical field of medicines, and relates to application of an azone compound as the alpha-glucosidase inhibitor. The compound has the following structure: # imgabs0 #. The compound Peniazathilone A is obtained by extracting, separating and purifying an ethyl acetate extract phase of a fermented product of Penicillium sp from soil, and the alpha-glucosidase inhibition activity of the compound is evaluated by adopting a pNPG method. Experimental results show that the IC50 value of the compound Peniazathilone A is 86.8 [mu] M (the IC50 value of a positive control acarbose is 5.97 mM), and the inhibition rate reaches 92.4% when the concentration of the compound is 0.466 mM. The compound has obvious activity of inhibiting alpha-glucosidase, is expected to be developed into a novel hypoglycemic drug, and has potential medical and health-care values.

The present invention provides a strain of Bifidobacterium adolescentis with the function of inhibiting α-glucosidase activity and secreting GLP-1 and its application, belonging to the field of functional microbial technology. The present invention isolates a strain of Bifidobacterium adolescentis B24728 from the feces of centenarians in Guangxi. The strain B24728 not only has the function of inhibiting α-glucosidase activity in vitro, but also has the function of high production of GLP-1, and animal experiments show that the strain B24728 has the efficacy of treating diabetes. At the same time, the strain B24728 is a human strain, has no species rejection reaction, and meets the safety requirements. Therefore, the strain B24728 and its culture can be used as food, health products or medicines for lowering blood sugar, and can be used to prepare medicines for the treatment of diabetes.

The invention discloses a composite double-protein hypoglycemic peptide as well as a preparation method and application thereof, and belongs to the technical field of animal and plant source double-protein active peptides. The method comprises the following steps: performing computer simulation enzyme digestion and virtual screening by utilizing bioinformatics to determine a protein raw material and protease, performing enzymolysis on animal and plant double proteins (soybean protein and casein) serving as raw materials by adopting neutral protease, and performing separation, purification and structural identification, thereby obtaining the protein. The protein peptide fragment with high alpha-glucosidase inhibitory activity is obtained by virtually screening molecular docking, and the amino acid sequences of the protein peptide fragment are shown as SEQ ID No: 6, SEQ ID No: 9 and SEQ ID No: 24. The compound double-protein peptide sequence provided by the invention has an inhibiting effect on the activity of alpha-glucosidase, can be used for preventing and treating diabetes mellitus, and can be used for long-term health care or treatment of people with impaired glucose tolerance or diabetics as a functional food ingredient.

The invention relates to a plant lactobacillus and application thereof in fermentation of a grape seed extract. The strain is named as FBL002, and is preserved in the Guangdong Microbial Culture Collection Center, the preservation address is the 5th floor of the Experimental Building, No.100 Court, Middle Xianlie Road, Xiaoxian District, Guangzhou City, Guangdong Province, and the preservation number is GDMCC No.66015. The tolerance of the plant lactobacillus provided by the invention to active ingredients in the grape seed extract is improved by 34%, and meanwhile, the activity of beta-glucosidase is remarkably improved to 204U / mL. In fermentation application, the strain shows excellent biotransformation performance, the content of total phenols and the content of total flavonoids in the fermented grape seed extract are increased by 45% and 98% respectively compared with an unfermented system, and meanwhile, the scavenging rate of antioxidant activity ABTS free radicals and the scavenging rate of DPPH are remarkably increased to 95%. The strain shows important application value in the fields of functional food development and natural cosmetic raw material production, and an innovative solution is provided for high-value utilization of plant resources.

The invention discloses application of an aglA gene in preparation of L-amino acid, and belongs to the technical field of biology. The application is the application of alpha-glucosidase or a substance for regulating and controlling the activity and / or content of the alpha-glucosidase in preparation of L-amino acid, and experiments prove that the aglA gene can remarkably improve the yield of the L-amino acid such as L-glutamic acid, L-lysine and L-threonine in a recombinant strain.

The invention relates to the technical field of biological fermentation, in particular to lactobacillus rhamnosus Lr-M8 and application thereof, and the preservation number of the lactobacillus rhamnosus Lr-M8 is CGMCC (China General Microbiological Culture Collection Center) No.3002. The lactobacillus rhamnosus Lr-M8 can effectively improve the oxidation resistance of medicinal and edible plant extracts of astragalus membranaceus, medlar, momordica grosvenori and folium mori, and can repair oxidase damage in a human body and regulate blood sugar balance. ABTS < + > free radical scavenging ability, DPPH free radical scavenging ability, total reducing power and iron ion reducing power (FRAP) of the fermented astragalus membranaceus, medlar, momordica grosvenori and mulberry leaves are remarkably improved; the influence on activity inhibition of alpha-amylase and alpha-glucosidase is stronger.

The invention relates to lactobacillus mucilaginosus and application thereof in fermented soybean milk. The lactobacillus mucus is preserved in the Guangdong Microbial Culture Collection Center on March 10, 2025, and the preservation number is GDMCC (China General Microbiological Culture Collection Center) No. 65866. The viable count of the fermented lactobacillus mucus in soybean milk is increased by 56%, meanwhile, the activity of beta-glucosidase is remarkably improved to 198 U / mL, and the degradation rate of total purine in soybean milk is 65.32%. In fermentation application, the total polyphenol content and the total flavone content in fermented soybean milk after fermentation are respectively increased by 39.56% and 52.32% compared with those in an unfermented system, the daidzein content and the genistein content in the fermented soybean milk after fermentation are respectively increased by 256.3% and 356.3% compared with those in the unfermented system, and meanwhile, the antioxidant activity ABTS free radical scavenging rate and the antioxidant activity DPPH scavenging rate are obviously increased to 89.6% and 94.8% respectively. The strain shows important application value in the fields of functional food development and natural cosmetic raw material production, and an innovative solution is provided for high-value utilization of plant resources.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus mucus fermentation TY-M26 and application of the lactobacillus mucus fermentation TY-M26, and the preservation number of the lactobacillus mucus fermentation TY-M26 is CGMCC (China General Microbiological Culture Collection Center) No. 32238. The lactobacillus mucilaginosus TY-M26 has high inhibitory activity on alpha-glucosidase activity, and animal experiments prove that the lactobacillus mucilaginosus TY-M26 can significantly relieve diabetes characteristics of mice with type II diabetes, significantly reduce fasting blood-glucose level, significantly improve insulin resistance and serum insulin level, significantly reduce serum Glu level and serum TG level, and can be used for preparing medicines for treating diabetes mellitus. The pathological injury of pancreatic tissues is obviously improved; the lactobacillus mucilaginosus TY-M26 has the advantages that the lactobacillus mucilaginosus TY-M26 can be used for preparing the lactobacillus mucilaginosus TY-M26, the serum ALT level and the serum AST level can be obviously reduced, the pathological injury of liver tissues can be obviously improved, a certain protection effect on the liver is achieved, and the lactobacillus

The invention relates to a small cellar sauced vinasse hydrolysis peptide with alpha-glucosidase inhibitory activity and a preparation method thereof. Five small cellar Maotai-flavor vinasse hydrolytic peptides with alpha-glucosidase inhibitory activity are prepared through vinasse protein preparation, enzymolysis, separation and purification and identification, and the sequences of the five small cellar Maotai-flavor vinasse hydrolytic peptides are AAPFYAL, LAYPQ, IRLPFNQI, INPALPW and ATPVFL respectively. The molecular docking analysis result shows that the interaction between the vinasse polypeptide and the amino acid residues of the alpha-glucosidase active pocket is mainly based on hydrogen bonds, electrostatic binding hydrophobic interaction and pi-pi interaction. Pharmacophore construction and matching analysis show that the vinasse polypeptide has a common characteristic structure composed of a positive ion center and three hydrogen bond donors and plays a key role in enzyme inhibition. The small cellar sauced vinasse polypeptide with alpha-glucosidase inhibitory activity prepared by the invention can be used for developing health-care foods and medicines for reducing blood sugar.

The invention discloses a thiochromanone derivative containing a thiosemicarbazone structure and application of the thiochromanone derivative, relates to the technical field of medicines, and particularly relates to the technical field that the compound has better oxidation resistance and alpha-glucosidase resistance activity, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to ABTS clearance activity is 2.86 [mu] g / mL, the IC50 value of the compound 1-(7-chloro-4, 4-dioxothiochromanone-3-N-propyl) thiosemicarbazone to alpha-glucosidase inhibition activity is 9.51 [mu] g / mL, and the effect is the best and is superior to that of a control agent vitamin E and acarbose. The thiochromanone derivative containing the thiosemicarbazone structure has a general formula shown in the specification,

The invention discloses trichosanthes kirilowii maxim seed polypeptide with alpha-glucosidase inhibitory activity and a preparation method thereof. Four Trichosanthes kirilowii Maxim seed polypeptides with alpha-glucosidase inhibitory activity are obtained through Trichosanthes kirilowii Maxim seed protein preparation, enzymolysis, separation and purification and identification, and the sequences of the four Trichosanthes kirilowii Maxim seed polypeptides are respectively HRQTWD, HANRLP, FGGVGER and SYAPEDR. Molecular docking analysis results show that interaction between the trichosanthes kirilowii maxim seed hydrolytic peptide and amino acid residues of an alpha-glucosidase active pocket is mainly based on hydrogen bonds, electrostatic interaction and hydrophobic interaction, and residues D203, D327, D443, F450, D542 and F575 are key binding sites interacting with the four polypeptides. The trichosanthes kirilowii maxim seed polypeptide with alpha-glucosidase inhibitory activity prepared by the invention can be used as a food-borne hypoglycemic component to be used for developing health-care foods and medicines for reducing blood sugar.

The invention discloses a polysaccharide component for inhibiting activity of alpha-glucosidase in the technical field of traditional Chinese medicine, the polysaccharide component is HCPN or HCPA1, the HCPN is mainly heteropolysaccharide composed of four monosaccharides, and the monosaccharides comprise Man, Glc, Gal and Ara; the HCPA1 is heteropolysaccharide mainly composed of seven monosaccharides, and the monosaccharides of the HCPA1 comprise Man, GlcA, Rha, GalA, Glc, Gal and Ara. The alpha-glucosidase inhibition ratio of HCPN and HCPA1 is measured, and the result shows that the alpha-glucosidase inhibition ratio of HCPN and HCPA1 is higher than that of a positive drug acarbose.

In the present application, by knocking out the BG gene in Trichoderma reesei PX3 (a strain of cellulase transcription activator that can be activated continuously), the BG activity can be reduced under the condition of not reducing or even increasing the filter paper enzyme activity of the enzyme system, and a low BG enzyme activity and high filter paper enzyme activity strain is constructed. This strategy can avoid the negative impact on cellulase production after BG knockout, and the obtained strain can be used for efficient production of cellobiose or as a chassis strain for producing cellulase.

The present application relates to a kind of chalcone amide alpha-glucosidase inhibitors and its preparation and application, the inhibitor structural formula is: preparation method specifically is (1) after 2-hydroxyacetophenone, sodium hydroxide and methyl p-formylbenzoate are reacted, intermediate in formula (a) is obtained after post-processing;(2) intermediate in formula (a) is dissolved in organic solvent and potassium hydroxide is reacted, after reaction, intermediate in formula (b) is obtained after post-processing;(3) intermediate in formula (b) and substituted aniline are dissolved in organic solvent, after reaction, the inhibitor shown in formula (c) is obtained after post-processing.Compared with prior art, the compound of the present application is novel, and experiments show that it has good alpha-glucosidase inhibitory activity, and can be used for preparing alpha-glucosidase activity inhibiting drug.

The invention belongs to the technical field of fermentation engineering, and particularly relates to lactobacillus reuteri with high beta-glucosidase activity and application of the lactobacillus reuteri in fermentation of sea-buckthorn juice. The preservation number of the strain is CGMCC NO: 33026. The strain is an adaptive evolutionary probiotic, can improve the activity and tolerance of the probiotic, has a good application effect in fermentation of sea-buckthorn juice, can maintain high bacterial activity, and has a good application prospect in fermentation of sea-buckthorn juice. According to the sea-buckthorn juice, the viable count of the sea-buckthorn juice is kept at 9.12-9.37 log (cfu / mL), compared with unfermented sea-buckthorn juice, the fermented sea-buckthorn juice has higher total phenol content and total flavone content, the antioxidant activity of the fermented sea-buckthorn juice is improved, the total phenol content can reach 545 mg / 100 mL and is increased by 95% compared with the unfermented sea-buckthorn juice, meanwhile, the method is a safe method without introduction of exogenous genes, can be applied to food, and has wide application prospects. Good application prospects are realized.

The present invention belongs to the field of biotechnology, and discloses a Bacillus subtilis strain from Tibetan pigs, with the classification name of Bacillus subtilis Yirun2024, the Latin name of Bacillus subtilis Yirun2024, the preservation number of CCTCC NO: M 20241752, the preservation date of August 7, 2024, the preservation unit of China Center for Type Culture Collection, and the preservation address of Wuhan University, Wuhan, China. This Bacillus subtilis has high cellulase production. After 12 h of fermentation in a shake flask, the activities of endoglucanase, exoglucanase and β-glucosidase are respectively as high as 2902.72 U / mL, 11026.33 U / mL and 2983.04 U / mL, far exceeding those of similar engineering bacteria. At the same time, the present invention also provides the application of this Bacillus subtilis, which is of great significance in promoting the application field of fiber resources. At the same time, this strain can maintain a relatively high survival rate in a high-temperature environment.

This invention belongs to the field of carbon nanomaterials technology, specifically disclosing a method for preparing and applying carbon dots from *Pu Di Lan* (a type of medicinal herb) residue. The specific steps are as follows: dried *Pu Di Lan* residue is pulverized using a cell wall breaker to obtain *Pu Di Lan* residue powder; the powder is then reacted using a hydrothermal method; the reaction solution is collected; the reaction solution is centrifuged, and the supernatant is collected; the supernatant is filtered, and the filtrate is collected; the filtrate is dialyzed, and the retaining liquid is collected; the retaining liquid is freeze-dried to obtain the *Pu Di Lan* residue carbon dots. The obtained *Pu Di Lan* residue carbon dots exhibit blue fluorescence under a 365 nm ultraviolet lamp, and their surface is rich in functional groups such as hydroxyl and carboxyl groups, showing good hydrophilicity. The *Pu Di Lan* residue carbon dots promote β-D-glucosidase activity and can be used in food processing; simultaneously, the fluorescence of the *Pu Di Lan* residue carbon dots is highly sensitive to β-D-glucosidase, and β-D-glucosidase activity can be detected by fitting a linear regression equation with a standard solution.

This invention relates to the field of soil treatment technology, specifically a method and its application for reducing compound fungicides in soil-plant systems by combining nano-silica and nitrification inhibitors. Nitrification inhibitors are used as a nitrogen management measure, and the application of nanomaterials influences soil abiotic properties and bacterial communities to drive the degradation of paclobutrazol and carbendazim. The application of nitrification inhibitors (DCD) produces multiple effects: significantly reducing carbendazim residues in soil-plant systems, paclobutrazol residues in soil, and NO3 in plants. ‑ -N and promote the content of soluble sugars and proline in plants. DCD reduces the activity of the soil electron transport system and β-glucosidase activity, while the addition of nano-SiO2 can mitigate this negative effect. Nano-SiO2 selectively enhances the performance of DCD in reducing compound fungicide residues in pak choi and reducing paclobutrazol residues, but hinders the degradation of carbendazim in pak choi.

The present invention provides an α-glucosidase mutant, a kit and its application. The α-glucosidase mutant includes: (a) a protein mutated based on the α-glucosidase shown in SEQ ID NO: 1, and the mutation includes mutations occurring at one or more sites of V298, E283 or R338; (b) a protein having more than 70% homology with the amino acid sequence defined in (a) and having α-glucosidase activity. It can solve the problem of low specific enzyme activity of α-glucosidase in the prior art and is applicable to the field of α-glucosidase modification.

The invention belongs to the field of food science and engineering, and discloses a preparation method of an active medicinal and edible composite nutrient AMCN with an anti-aging effect, and the preparation method comprises the following steps: putting a ganoderma lucidum monoclonal strain into a liquid culture medium for controllable culture to obtain supernate with beta-glucosidase activity of over 100mU / mL; and adding rhizoma polygonati powder, lucid ganoderma powder and mulberry leaf powder, carrying out enzymatic biotransformation, carrying out lactobacillus plantarum fermentation, adding a freeze-drying protective additive, carrying out freeze-drying, grinding to obtain the active medicinal and edible composite nutrient AMCN, and storing the finished product in a dry and dark place. The active medicinal and edible composite nutrient can be used for preparing anti-aging functional foods or nutritional health-care products. A D-galactose induced zebrafish aging model verifies that the active medicinal and edible composite nutrient prepared by the application plays an anti-aging role by relieving oxidative stress, inhibiting cell aging and maintaining telomere stability, can reduce beta-galactosidase activity and intracellular ROS (reactive oxygen species) level, improves telomerase protein concentration, and has a good anti-aging effect. And the telomere length can be effectively recovered by medium and high concentrations.

A Pediococcus acidilactici QM70-3 and its application in the fermentative conversion for preparing rare ginsenosides belong to the field of probiotic fermentation. The Pediococcus acidilactici QM70-3 was deposited at the China Center for Type Culture Collection on February 25, 2025, with the deposit number of CCTCC NO: M 2025298. In the present invention, ginsenoside Re is used as the raw material, and the rare ginsenosides Rg2, Rg6, F4 and Rh1 are prepared by fermentative conversion using Pediococcus acidilactici QM70-3 with high β-glucosidase activity. After fermentation, the ginsenoside monomer Re can be completely converted into Rg2, Rg6, F4 and Rh1. This technology does not rely on processes such as alkali hydrolysis, high temperature and high pressure, and steam treatment, and has the characteristics of mild conditions, environmental friendliness and outstanding economy. The present invention provides a new way for the preparation of rare ginsenosides Rg2, Rg6, F4 and Rh1, and has good application prospects.

The invention discloses a pyrimidine derivative containing a thiosemicarbazide structure and application of the pyrimidine derivative, and relates to the technical field of medicines, the compound has good oxidation resistance and alpha-glucosidase resistance activity, and the compound is 2-(4, 4 '-difluorophenyl)-2-(4, 4'-difluorophenyl)-2-(4, 4 '-difluorophenyl)-2-(4, 4' The IC50 values of the compound 2-(4, 6-dimethyl pyrimidine-2-yl)-N-methylhydrazine-1-methylsulfamide on DPPH (1, 1-diphenyl-2-picrylhydrazyl) scavenging activity and ABTS (2, 2, 6-dimethyl pyrimidine-2-yl)-N-methylhydrazine-1-methylsulfamide are 3.96 mu g / mL and 2.01 mu g / mL respectively, the IC50 value of the compound 2-(4, 6-dimethyl pyrimidine-2-yl)-N-methylhydrazine-1-methylsulfamide on alpha-glucosidase inhibitory activity is 38.62 mu g / mL, the effect is best, and the compound 2-(4, 6-dimethyl pyrimidine-2-yl)-N-methylhydrazine-1 The pyrimidine derivative containing the thiosemicarbazide structure has a general formula shown in the specification, and is superior to control medicaments such as vitamin C, vitamin E and acarbose.

The invention discloses a low-GI biscuit with a blood sugar regulating function and a preparation method of the low-GI biscuit, and belongs to the technical field of food processing. The low-GI biscuits comprise water and oil wrappers and bakery shortening dough, and the water and oil wrappers comprise buckwheat flour, low-gluten flour, edible oil, yeast and baking soda; the bakery shortening dough comprises high amylose corn starch, corn starch, edible oil, ground cinnamon and salt. Through the synergistic effect of all the components, the activity of alpha-amylase and alpha-glucosidase is inhibited, carbohydrate digestion is delayed, and the GI value is reduced. The low-GI biscuit prepared by the preparation method disclosed by the invention has a crisp taste and an antibacterial effect, and a safe and effective food choice is provided for diabetics and crowds with blood glucose control.

This invention discloses a low glycemic index (GI) Hericium erinaceus (monkey head mushroom) steamed bun, belonging to the field of food processing and functional food applications. By weight, it is prepared from the following raw materials: 45-55 parts all-purpose flour, 28-35 parts Hericium erinaceus extract powder, 0.3-0.35 parts yeast, 15-18 parts water, 0.3-0.6 parts oil, and 0.7-0.9 parts sugar. This invention partially replaces the flour with Hericium erinaceus extract powder, fully utilizing the multiple mechanisms of action of Hericium erinaceus polysaccharides in forming a viscous gel in the digestive tract to slow down the contact between amylase and substrate, inhibiting α-amylase and α-glucosidase activity, and improving intestinal microecology and enhancing insulin sensitivity through dietary fiber. This allows the product to meet the low-GI food standard (GI<55), effectively filling the gap in low-GI steamed buns with Hericium erinaceus functional components as the core active ingredient. It has significant application value in the fields of diabetes management, weight control, and healthy staple foods.

The present invention belongs to the technical field of fermentation engineering, and specifically relates to a strain of Lactobacillus reuteri with high β-glucosidase activity and its application in fermented seabuckthorn juice. The strain is deposited with CGMCC NO: 33026; the strain is an adaptive evolution probiotic, which can improve the activity and tolerance of probiotics, has a good application effect in fermented seabuckthorn juice, can maintain a high bacterial activity, and its viable count is maintained at 9.12~9.37 log (cfu / mL), and compared with unfermented seabuckthorn juice, fermented seabuckthorn juice has a higher total phenol content and total flavonoid content, and the antioxidant activity of the fermented seabuckthorn juice is improved, and the total phenol content can reach 545 mg / 100 mL, which is 95% higher than that of unfermented seabuckthorn juice. It is also a safe method without introducing exogenous genes and can be used in food, and has good application prospects.

The application discloses a kind of complex fermentation inoculant for improving equol production, fermentation liquor and application thereof, belong to microbial fermentation technical field.The complex fermentation inoculant of the application, streptococcus thermophilus BLCC2-0025 and lactococcus lactis MP1001 have high β-glucosidase activity, and low activity glycoside form is converted into high activity daidzein;Salivary lactobacillus LS1101 and lactobacillus gregius 0010 have the activity of further converting daidzein into equol;Four strains of bacteria are used in combination, which can synergistically improve the content of equol.The fermentation liquor prepared by fermenting pueraria extract with the complex fermentation inoculant of the application can target regulate intestine-ovary axis, significantly improve the reproductive function of POF mice, relieve ovarian oxidative stress and accurately regulate intestinal flora balance, providing a safe and effective preparation and application scheme for non-hormone intervention of premature ovarian failure.

The application provides a compound shown in formula I or a pharmaceutically acceptable salt thereof: wherein R4 is selected from a hydroxyl group, an O-beta-D Glc group, and an O-beta-D Glc-(2-1)-alpha-L-Rha group; and R8 is selected from a hydroxyl group, an O-beta-D Glc group, and an O-beta-D Glc-(2-1)-alpha-L-Rha group; and the application provides the use of the compound in the preparation of a blood sugar reducing drug and in the inhibition of alpha-glucosidase activity, and has the beneficial effect that the application provides the use of zeylasteroside D and zeylasteroside J in the preparation of a blood sugar reducing drug and in the inhibition of alpha-glucosidase activity, and discloses the compound structure of zeylasteroside L and the use of the zeylasteroside L in the preparation of a blood sugar reducing drug and in the inhibition of alpha-glucosidase activity.

The invention discloses preparation and application of a corn polypeptide with functions of inhibiting amyloglucosidase activity and promoting GLP-1 secretion, and belongs to the technical field of functional food. And the corn polypeptide is PYPR, PPAPR and PLRP (Poly Lactic Polymerase Chain Reaction). The corn polypeptide is obtained by enzymolysis of corn protein through alkaline protease, and is novel in structure and easy to prepare. The corn polypeptide can inhibit the activity of amyloglucosidase in vitro, can significantly promote GLP-1 secretion, and can up-regulate the expression of gcg and gc3 genes related to GLP-1 synthesis and a polypeptide recognition receptor GPR93 by regulating Ca < 2 + > influx and an ATP signal channel, thereby improving the steady state of blood glucose. The invention provides reference for developing functional food or health care products with the functions of reducing blood sugar and promoting secretion of insulin.